Clinical trial
Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?
Name
GaziosmanpasaTREHm
Description
Women's ovarian reserve and fertility were compared before and after 2 doses of vaccination
Trial arms
Trial start
2022-02-01
Estimated PCD
2022-10-20
Trial end
2022-11-30
Status
Completed
Treatment
sars cov 2 biontec vaccine
volunteers will be expected to receive 2 doses of vaccine
Arms:
Pre-vaccine ovarian reserve and fertility status
Size
64
Primary endpoint
Ovarian reserve tests and fertility status of 74 women before and after vaccination
6 months after receiving the 2nd dose of vaccine
Eligibility criteria
Inclusion Criteria:
* between 18-45 years old
* have ever had a covid vaccine
* not be infected with covid 19
Exclusion Criteria:
* pregnancy
* diagnosis of any kind of cancer
* oral contraceptive usage
* endometrioma
* PCOS
* menopause
* menstrual irregularity
* premature ovarian insufficiency
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '8 Months', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 64, 'type': 'ACTUAL'}}
Updated at
2023-02-22
1 organization
1 product
4 indications
Organization
Gaziosmanpasa Research and Education HospitalProduct
SARS-CoV-2 BioNTech VaccineIndication
COVID-19Indication
Ovarian insufficiencyIndication
Fertility DisordersIndication
Adverse Vaccine Reaction